C-peptide as a therapeutic tool in diabetic nephropathy

American Journal of Nephrology

Volumn 31, Issue 5, 2010, Pages 389-397

  Hills, Claire E ^a   Brunskill, Nigel J ^b   Squires, Paul E ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

C peptide; Diabetic nephropathy

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATE; ALBUMIN; C PEPTIDE; CALCIUM; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROINSULIN; PROTEIN KINASE C; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

CALCIUM CELL LEVEL; DIABETIC NEPHROPATHY; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; GLOMERULUS FILTRATION; HUMAN; HYPERGLYCEMIA; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SYNTHESIS; KIDNEY HYPERTROPHY; KIDNEY PROXIMAL TUBULE; MEDICAL LITERATURE; MEDLINE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; RENAL PROTECTION; REVIEW; ANIMAL; BIOLOGICAL MODEL; BLOOD; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE COURSE; FIBROSIS; METABOLISM; PATHOLOGY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FIBROSIS; HUMANS; HYPERGLYCEMIA; MODELS, BIOLOGICAL; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE III; PROTEIN KINASE C; SODIUM-POTASSIUM-EXCHANGING ATPASE; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 77950055170     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000289864     Document Type: Review

References (56)

1. Rubenstein AH, Melani F, Pilkis S, Steiner DF: Proinsulin. Secretion, metabolism, immunological and biological properties. Postgrad Med J 1969; 45: 476-481.
2. Wójcikowski C, Maier V, Dominiak K, Fussgänger R, Pfeiffer EF: Effects of synthetic rat C-peptide in normal and diabetic rats. Diabetologia 1983; 25: 288-290.
3. Samnegård B, Jacobson SH, Jaremko GH, Johansson B-L, Sjöquist B: Effects of C-peptide on glomerular and renal size and renal function in diabetic rats. Kidney Int 2001; 60: 1258-1265.
4. Sjoquist M, Huang W, Johansson B-L: Effects of C-peptide on renal function at the early stage of experimental diabetes. Kidney Int 1998; 54: 758-764.
5. Maezawa Y, Yokote K, Sonezaki K, Fujimoto M, Kobayashi K, Kawamura H, Tokuyama T, Takemoto M, Ueda S, Kuwaki T, Mori S, Wahren J, Saito Y: Influence of C-peptide on early glomerular changes in diabetic mice. Diabetes Metab Res Rev 2006; 22: 313-322.
6. Samnegård B, Jacobson SH, Jaremko G, Johansson BL, Ekberg K, Isaksson B, Eriksson L, Wahren J, Sjöquist M: C-peptide prevents glomerular hypertrophy and mesangial matrix expansion in diabetic rats. Nephrol Dial Transplant 2005; 20: 532-538.
7. Wallerath T, Kunt T, Forst T: Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide. Nitric Oxide 2003; 9: 95-102.
8. Al-Rasheed NM, Willars GB, Brunskill NJ: C-peptide signals via Gα i to protect against TNF-α-mediated apoptosis of opossum kidney proximal tubular cells. J Am Soc Nephrol 2006; 17: 986-995.
9. Hills CE, Al-Rasheed N, Al-Rasheed N, Willars GB, Brunskill NJ: C-peptide reverses TGF-β 1 -induced changes in renal proximal tubular cells: implications for treatment of diabetic nephropathy. Am J Physiol Renal Physiol 2009; 296:F614-F621.
10. United States Renal Data System (USRDS): Annual data report: atlas of end-stage renal disease in the United States. Bethesda, National Institute of Health/National Institute of Diabetes and Digestive and Kidney Disease, 2003.
11. Soldatos G, Cooper ME: DN: Important pathophysiologic mechanisms. Diabetes Res Clin Pract 2008; 82(suppl 1):S75-S79.
12. Mauer SM, Steffes MW, Ellis EN: Structuralfunctional relationships in DN. J Clin Invest 1984; 74: 1143-1155.
13. Hostetter TH, Troy JL, Brenner BM: Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 1981; 19: 410-415.
14. Steffes MW, Osterby R, Chavers B, Mauer SM: Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 1989; 38: 1077-1081.
15. Krolewski AS, Laffel LM, Krolewski M, Quinn M, Warram JH: Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995; 332: 1251-1255.
16. Gnudi L, Gruden G, Viberti G: Pathogenesis of diabetic nephropathy; in Pickup JC, Williams G (eds): Textbook of Diabetes, ed 3. Oxford, Blackwell Science, 2003, pp 52.1- 53.21.
17. Fiorina P, Folli F, Maffi P, Placidi C, Venturini M, Finzi G, Bertuzzi F, Davalli A, D'Angelo A, Socci C, Gremizzi C, Orsenigo E, La Rosa S, Ponzoni M, Cardillo M, Scalamogna M, Del Maschio A, Capella C, Di Carlo V, Secchi A: Islet transplantation improves vascular diabetic complications in patients with diabetes who underwent kidney transplantation: a comparison between kidney-pancreas and kidney-alone transplantation. Transplantation 2003; 27: 1296-1301.
18. Lee TC, Barshes NR, Agee EE, O'Mahoney CA, Brunicardi FC, Goss JA: The effect of whole organ pancreas transplantation and PIT on diabetic complications. Curr Diab Rep 2006; 6: 323-327.
19. Johansson BL, Sjöberg S, Wahren J: The influence of human C-peptide on renal function and glucose utilization in type 1 (insulin- dependent) diabetic patients. Diabetologia 1992; 35: 121-128.
20. Johansson BL, Kernell A, Sjöberg S, Wahren J: Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1. J Clin Endocrinol Metab 1993; 77: 976-981.
21. Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J: Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus. Diabet Med 2000; 17: 181-189.
22. Nordquist L, Brown R, Fasching A, Persson P, Palm F: Proinsulin C-peptide reduces diabetes- induced glomerular hyperfiltration via efferent arteriole dilation and inhibition of tubular sodium reabsorption. Am J Physiol Renal Physiol 2009; 297:F1265-F1272.
23. Nordquist L, Moe E, Sjöquist M: The C-peptide fragment EVARQ reduces glomerular hyperfiltration in streptozotocin-induced diabetic rats. Diabetes Metab Res Rev 2007; 23: 400-405.
24. Hills CE, Brunskill NJ: Cellular and physiological effects of C-peptide. Clin Sci 2009; 116: 565-574.
25. Hills CE, Brunskill NJ: C-peptide and its intracellular signalling. Rev Diabet Stud 2009; 6: 138-147.
26. Flatt PR, Swanston-Flatt SK, Hampton SM, Bailey CJ, Marks V: Specific binding of the C-peptide of proinsulin to cultured B cells from a transplantable rat islet cell tumor. Biosci Rep 1986; 6: 193-199.
27. Rigler R, Pramanik A, Jonasson P, Kratz G, Jansson O, Nygren PA, Stahl S, Ekberg K, Johansson BL, Uhlen S, Uhlen M, Jornvall H, Wahren J: Specific binding of proinsulin Cpeptide to human cell membranes. Proc Natl Acad Sci USA 1999; 96: 13318-13323.
28. Hoogwerf BJ, Bantle JP, Gaenslen HE, Greenberg BZ, Senske BJ, Francis R, Goetz FC: Infusion of synthetic human C-peptide does not affect plasma glucose, serum insulin, or plasma glucagon in healthy subjects. Metabolism 1986; 35: 122-125.
29. Ohtomo Y, Bergman T, Johansson BL, Jörnvall H, Wahren J: Differential effects of proinsulin C-peptide fragments on Na + ,K + - ATPase activity of renal tubule segments. Diabetologia 1998; 41: 287-291.
30. Vague P, Coste TC, Jannot MF, Raccah D, Tsimaratos M: C-peptide, Na + ,K + -ATPase, and diabetes. Exp Diabesity Res 2004; 1: 37-50.
31. Zhong Z, Kotova O, Davidescu A, Ehrén I, Ekberg K, Jörnvall H, Wahren J, Chibalin AV: C-peptide stimulates Na + ,K + -ATPase via activation of ERK-1/2 MAP kinases in human renal tubular cells. Cell Mol Life Sci 2004; 61: 2782-2790.
32. Tsimaratos M, Roger F, Chabardès D, Mordasini D, Hasler U, Doucet A, Martin PY, Féraille E: C-peptide stimulates Na + ,K + - ATPase activity via PKC-- in rat medullary thick ascending limb. Diabetologia 2003; 46: 124-131.
33. Zhong Z, Davidescu A, Ehrén I, Ekberg K, Jörnvall H, Wahren J, Chibalin AV: C peptide stimulates ERK-1/2 and JNK MAP kinases via activation of protein kinase C in human renal tubular cells. Diabetologia 2005; 48: 187-197.
34. Forst T, Dufayet De La Tour D, Kunt T: Effects of proinsulin C-peptide on nitric oxide, microvascular blood flow and erythrocyte Na + ,K + -ATPase activity in diabetes mellitus type 1. Clin Sci 2000; 98: 283-290.
35. Ohtomo Y, Aperia A, Sahlgren B, Johansson BL, Wahren J: C peptide stimulates rat renal tubular Na + /K + -ATPase activity in synergism with neuropeptide Y. Diabetologia 1996; 39: 199-205.
36. Chen CC: Differentiation of renal Na + -K + - ATPase in control and streptozotocin-induced diabetic mice by G-protein acting toxins and phorbol esters. Eur J Pharmacol 1992; 225: 275-279.
37. Kunt T, Schneider S, Pfutzner A: The effect of human proinsulin C peptide on erythrocyte deformability in patients with type 1 diabetes mellitus. Diabetologia 1999; 42: 465-471.
38. Hach T, Forst T, Kunt T, Ekberg K, Pfützner A, Wahren J: C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients. Exp Diabetes Res 2008; 2008: 730594.
39. Meyer JA, Froelich JM, Reid GE, Karunarathne WK, Spence DM: Metal-activated Cpeptide facilitates glucose clearance and the release of a nitric oxide stimulus via the GLUT-1 transporter. Diabetologia 2008; 51: 175-182.
40. Freedman JE, Loscalzo J, Barnard MR: Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 1997; 100: 350-356.
41. Kotsis DH, Spence DM: Detection of ATPinduced nitric oxide in a biomimetic circulatory vessel containing an immobilized endothelium. Anal Chem 2003; 75: 145-151.
42. Kitamura T, Kimura K, Makondo K, Furuya DT, Suzuki M, Yoshida T, Saito M: Proinsulin C peptide increases nitric oxide production by enhancing mitogen-activated protein kinase-dependent transcription of endothelial nitric oxide synthase in aortic endothelial cells of Wistar rats. Diabetologia 2003; 46: 1698-1705.
43. Wallerath T, Kunt T, Forst T, Closs EI, Lehmann R, Flohr T, Gabriel M, Schäfer D, Göpfert A, Pfützner A, Beyer J, Förstermann U: Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide. Nitric Oxide 2003; 9: 95-102.
44. Subasinghe W, Spence DM: Simultaneous determination of cell aging and ATP release from erythrocytes and its implications in type 2 diabetes. Anal Chim Acta 2008; 618: 227-233.
45. Meyer JA, Subasinghe W, Sima AA: Zinc-activated C-peptide resistance to the type 2 diabetic erythrocyte is associated with hyperglycemia- induced phosphatidylserine externalization and reversed by metformin. Mol Biosyst 2009; 5: 1157-1162.
46. Freyburger G, Gin A, Heape A: Phospholipid and fatty acid composition of erythrocytes in type 1 and type 2 diabetes. Metab Clin Exp 1989; 38: 673-678.
47. Dumaswala UJ, Wilson MJ, Wu YL, Wykle J, Zhuo L, Douglass LM, Daleke DL: Glutathione loading prevents free radical injury in red blood cells after storage. Free Radic Res 2000; 33: 517-529.
48. Magalhães FO, Gouveia LM, Torquato MT: Metformin increases blood flow and forearm glucose uptake in a group of non-obese type 2 diabetes patients. Horm Metab Res 2006; 38: 513-517.
49. Muller S, Denet S, Candiloros H, Barrois R, Wiernsperger N, Donner M, Drouin P: Action of metformin on erythrocyte membrane fluidity in vitro and in vivo. Eur J Pharmacol 1997; 337: 103-110.
50. Hohenstein B, Hugo CP, Hausknecht B, Boehmer KP, Riess RH, Schmieder RE: Analysis of NO synthase expression and clinical risk factors in human diabetic nephropathy. Nephrol Dial Transplant 2008; 23: 1346-1354.
51. Kamikawa A, Ishii T, Shimada K, Makondo K, Inanami O, Sakane N, Yoshida T, Saito M, Kimura K: Proinsulin C-peptide abrogates type-1 diabetes-induced increase of renal endothelial nitric oxide synthase in rats. Diabetes Metab Res Rev 2008; 24: 331-338.
52. Samnegård B, Jacobson SH, Johansson BL, Ekberg K, Isaksson B, Wahren J, Sjöquist M: C-peptide and captopril are equally effective in lowering glomerular hyperfiltration in diabetic rats. Nephrol Dial Transplant 2004; 6: 1385-1391.
53. Katz A, Caramori ML, Sisson-Ross S, Groppoli T, Basgen JM, Mauer M: An increase in the cell component of the cortical interstitium antedates interstitial fibrosis in type 1 diabetic patients. Kidney Int 2002; 61: 2058-2066.
54. Hills CE, Squires PE: TGF-β1 - induced epithelial- to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. Am J Nephrol 2010; 31: 68-74.
55. Ziyadeh FN: The extracellular matrix in DN. Am J Kidney Dis 1993; 22: 736-744.
56. Dennler S, Itoh S, Vivien D, Dijke P, Huet S, Gauthier J: Direct binding of Smad 3 and Smad 4 to critical TGF-β inducible elements in the promoter of the human plasminogen activator inhibitor-type 1 gene. EMBO J 1998; 17: 3091-3100.